High Blood Pressure and Sleep Apnea in Diabetic Macular Edema

Overview

Macular edema remains a major cause of vision impairment in diabetic patients. Its pathogenesis is multifactorial and incompletely understood. Systemic factors seam to play a role in this pathogenesis, including high blood pressure. The objective of the study is to evaluate the effect of an intensified intervention on blood pressure and sleep apnea with that of conventional treatment in patients with type 2 diabetes and diabetic macular edema.

Full Title of Study: “Role of High Blood Pressure and Sleep Apnea in Type 2 Diabetic Macular Edema”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2014

Detailed Description

Patients with type 2 diabetes and macular edema involving the center of the macula in both eyes will be randomly assigned to receive conventional treatment in accordance with national guidelines or to receive intensive treatment, with a systematic screening for sleep apnea and /or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected. The primary outcome will be the percentage of patients having a sustained 50% or more-decrease in retinal thickening at 1 year. Secondary outcomes will be the percentage of patients having a 2 ETDRS lines or more-increase in visual acuity at one year, number of ocular interventions in each group, prevalence of sleep apnea and uncontrolled high blood pressure in the intervention group.

Interventions

  • Behavioral: high blood pressure treatment
    • over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
  • Behavioral: sleep apnea treatment
    • over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
  • Behavioral: diabetic macular edema treatment
    • over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months

Arms, Groups and Cohorts

  • Experimental: intensive treatment
    • with a systematic screening for sleep apnea and/or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected
  • Active Comparator: conventional treatment
    • in accordance with national guidelines

Clinical Trial Outcome Measures

Primary Measures

  • The primary outcome will be the percentage of patients having a sustained 50% or more-decrease in retinal thickening at 1 year, assessed with OCT in the study eye.
    • Time Frame: M13

Secondary Measures

  • Percentage of patients having a 2 ETDRS lines or more-increase in visual acuity at one year in the study eye
    • Time Frame: M13
  • Number of ocular interventions (laser photocoagulation, intra ocular injections) in each group at one year in the study eye
    • Time Frame: M6-9
  • Progression of diabetic retinopathy in each group at one year according to the International DR classification in the study eye
    • Time Frame: M13
  • Comparison of blood pressure in each group at one year
    • Time Frame: M13

Participating in This Clinical Trial

Inclusion Criteria

  • Patient with type 2 diabetes, aged 18 years or more – Bilateral diabetic macular edema involving the center of the macula with central retinal thickness 300 µm or more Exclusion Criteria:

  • Patient with type 1 diabetes – Tractional macular edema – Patient with renal insufficiency : clearance of creatinin < 30 ml/min according to COCROFT or MDRD, patient under dialysis – Other causes for macular edema (uveitis, epiretinal membrane) – Proliferative diabetic retinopathy requiring panretinal photocoagulation at inclusion – Cataract surgery or panretinal photocoagulation during the 6 months before inclusion, laser photocoagulation at the posterior pole or intra ocular steroid injection during the 3 months before inclusion – Any ocular condition precluding access to the posterior pole, or ocular pathologies not related to diabetes (age related macular degeneration venous occlusion…) – Previous vitrectomy in the eyes – Pregnant or breast-feeding female

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pascale MASSIN, MD,PhD, Principal Investigator, Assistance Publique – Hôpitaux de Paris

References

Paques M, Massin P, Sahel JA, Gaudric A, Bergmann JF, Azancot S, Levy BI, Vicaut E. Circadian fluctuations of macular edema in patients with morning vision blurring: correlation with arterial pressure and effect of light deprivation. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4707-11. doi: 10.1167/iovs.05-0638.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.